Anti-Rheumatic Rx
2 years ago
Steroid-sparing in PMR: methotrexate most used, but what is the evidence?
Christian Dejaco says: variable at best.
We need a proper RCT - and it’s on its way. @Sarah_L_Mackie @profbdasgupta @DrMaxYates1 @CatherineL_Hill @drceowen #ACR22 @RheumNow https://t.co/dxaPdVcOPQ
2 years ago
Lillegraven @SiriLillegraven ARCTIC REWIND. RA patients flare-free on half-dose csDMARD x 12 months - randomised to continue or stop. Flare 38% vs 17% over 12 months. DAS remission 96% vs 90%. Absence radiograph prog 84% vs 69% @RheumNow #ACR22 Abstr#2013 https://t.co/uOwd8Io5wZ https://t.co/SKWPE7GBrx
2 years ago
NSAIDs and CV risk in Inflammatory Arthritis
Dr. Richard Conway discusses abstract 1207, being presented #ACR22 meeting.
https://t.co/CjU2YbA3tk https://t.co/bHE4xw2IRF
2 years ago
Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty…
2 years ago
Torgutalp et al. Higher NSAID intake associated reduced spinal progression in AxSpA esp. r-AxSpA. Cox-2 may have greater effect than other NSAIDs. @RheumNow #ACR22 Abstr#1492 https://t.co/bGH6bBo7AD https://t.co/XBFV410Y2p
2 years ago
TOFA and MTX: which one to withdraw first?
RCT in 100+ RA pts in remission after 1 yr, 1 yr follow-up
Withdraw MTX grp: Remission 30% LDA 40%
Withdraw TOFA grp: Remission 50% LDA 65%
diff NS small sample
8 SAEs, 72% recovery
https://t.co/tMnet32TWF
Abs#1586 #ACR22 @Rheumnow https://t.co/PWnkWYdlGk
2 years ago
Uggh!
What would you do if your pt gets pregnant while on MTX & loses her baby, are you liable for accidental abortion? Should you advise termination if a pregnant pt’s health is deteriorating? @GreerDonley (#law professor) on theoretical risks #ACR22 @rheumnow https://t.co/L4FBWcKZnE